Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Operating Income (2017 - 2025)

Crinetics Pharmaceuticals has reported Operating Income over the past 9 years, most recently at -$133.7 million for Q4 2025.

  • Quarterly results put Operating Income at -$133.7 million for Q4 2025, down 41.08% from a year ago — trailing twelve months through Dec 2025 was -$516.8 million (down 52.5% YoY), and the annual figure for FY2025 was -$516.8 million, down 52.5%.
  • Operating Income for Q4 2025 was -$133.7 million at Crinetics Pharmaceuticals, up from -$142.6 million in the prior quarter.
  • Over the last five years, Operating Income for CRNX hit a ceiling of -$22.9 million in Q1 2021 and a floor of -$142.6 million in Q3 2025.
  • Median Operating Income over the past 5 years was -$56.0 million (2023), compared with a mean of -$67.7 million.
  • Biggest five-year swings in Operating Income: plummeted 64.99% in 2022 and later decreased 23.12% in 2023.
  • Crinetics Pharmaceuticals' Operating Income stood at -$30.9 million in 2021, then crashed by 53.96% to -$47.6 million in 2022, then plummeted by 31.76% to -$62.7 million in 2023, then plummeted by 51.21% to -$94.7 million in 2024, then crashed by 41.08% to -$133.7 million in 2025.
  • The last three reported values for Operating Income were -$133.7 million (Q4 2025), -$142.6 million (Q3 2025), and -$129.1 million (Q2 2025) per Business Quant data.